| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. | Liver Int | 2013 | 1.43 |
| 2 | Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. | Hepatology | 2014 | 1.05 |